7 Stocks Under $10 Making Big Moves

As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Westmoreland Coal

  • Thursday's Range: $7.14-$7.55
  • 52-Week Range: $3.44-$30.92
  • Thursday's Volume: 337,000
  • Three-Month Average Volume: 332,173

Westmoreland Coal  (WLB) , through its subsidiaries, operates as an energy company. This stock closed up 3% to $7.49 in Thursday's trading session.

From a technical perspective, Westmoreland Coal spiked notably higher on Thursday right off its 20-day moving average of $7.20 a share with decent upside volume flows. This jump to the upside is now quickly pushing shares of Westmoreland Coal within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term resistance levels at $7.55 a share to Thursday's intraday high of $7.56 a share with high volume.

Traders should now look for long-biased trades in Westmoreland Coal long as it's trending above some near-term support at $7 a share or above its 50-day moving average of $6.60 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 332,173 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8.05 to $8.16, or even $9 to its 200-day moving average of $9.58 a share.

BioCryst Pharmaceuticals

  • Thursday's Range: $2.87-$2.99
  • 52-Week Range: $1.63-$16.83
  • Thursday's Volume: 770,000
  • Three-Month Average Volume: 1.57 million

BioCryst Pharmaceuticals  (BCRX) , a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. This stock traded up 2.7% to $2.97 in Thursday's trading session.

From a technical perspective, BioCryst Pharmaceuticals spiked notably higher on Thursday right above its 20-day moving average of $2.79 a share with lighter-than-average volume. This stock has been uptrending strong over the last two months and change, with shares moving higher off its new 52-week low of $1.63 a share to its recent high of $3.24 a share. During that move, shares of BioCryst Pharmaceuticals have been making mostly higher lows and higher highs, which is bullish technical price action. This spike to the upside on Thursday is now quickly pushing this stock within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some key overhead resistance levels at $3 to $3.24 a share with high volume.

Traders should now look for long-biased trades in BioCryst Pharmaceuticals s as long as it's trending above its 50-day moving average of $2.72 a share or above more near-term support at $2.67 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.57 million shares. If that breakout develops soon, then this stock will set up to re-fill some of its previous gap-down-day zone from February that started near $7 a share.

Rockwell Medical

  • Thursday's Range: $7.84-$8.51
  • 52-Week Range: $5.47-$18.90
  • Thursday's Volume: 563,000
  • Three-Month Average Volume: 627,297

Rockwell Medical  (RMTI)  operates as an integrated biopharmaceutical company in the U.S. and internationally. This stock traded up 6% to $8.39 in Thursday's trading session.

From a technical perspective, Rockwell Medical ripped sharply higher on Thursday and broke out above some near-term overhead resistance at $8.21 a share with decent upside volume flows. This breakout pushed shares of Rockwell Medial into its previous gap-down-day zone from March that started near $10.50 a share. Market players should now look for a continuation move to the upside in the short-term if this stock manages to clear Thursday's intraday high of $8.51 a share with strong upside volume flows.

Traders should now look for long-biased trades in Rockwell Medical as long as it's trending above some near-term support at around $7.50 a share and then once it sustains a move or close above Thursday's intraday high of $8.51 a share with volume that hits near or above 627,297 shares. If that move gets underway soon, then this stock will set up to re-fill some more of its previous gap-down-day zone that started near $10.50 a share.

BioLineRx

  • Thursday's Range: $0.97-$1.02
  • 52-Week Range: $0.85-$2.80
  • Thursday's Volume: 261,000
  • Three-Month Average Volume: 444,681

BioLineRx  (BLRX) , a clinical stage biopharmaceutical development company, engages in identifying, in-licensing and developing therapeutic candidates that address unmet medical needs. This stock traded up 4.9% to $1.01 in Thursday's trading session.

From a technical perspective, BioLineRx spiked notably higher on Thursday right above some near-term support levels at 95 to 93 cents per share with lighter-than-average volume. This trend to the upside is now quickly pushing shares of BioLineRx within range of triggering a major breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term resistance levels at its 50-day moving average of $1.03 a share to its 20-day moving average of $1.04 a share and then above more resistance levels at $1.07 to $1.10 a share with high volume.

Traders should now look for long-biased trades in BioLineRx as long as it's trending above some key near-term support levels at 95 to 93 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 444,681 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.26 to $1.32, or even its 200-day moving average of $1.39 a share.

Achaogen

  • Thursday's Range: $3.16-$3.57
  • 52-Week Range: $2.59-$7.74
  • Thursday's Volume: 188,000
  • Three-Month Average Volume: 78,203

Achaogen  (AKAO) , a clinical-stage biopharmaceutical company, discovers, develops and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the U.S. This stock traded up 8.3% to $3.51 in Thursday's trading session.

From a technical perspective, Achaogen ripped sharply higher on Thursday back above its 50-day moving average of $3.42 a share with strong upside volume flows. This stock has been uptrending strong over the last few weeks, with shares moving higher off its new 52-week low of $2.59 a share to its intraday high on Thursday of $3.57 a share. During that uptrend, shares of Achaogen have been making mostly higher lows and higher highs, which is bullish technical price action. Market players should now look for a continuation move to the upside in the short-term if this stock manages to clear Thursday's intraday high of $3.57 a share with strong upside volume flows.

Traders should now look for long-biased trades in Achaogen as long as it's trending above Thursday's intraday low of $3.16 a share and then once it sustains a move or close above Thursday's intraday high of $3.57 a share with volume that hits near or above 78,203 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out is next major overhead resistance level at $4.32 a share.

TrueCar

  • Thursday's Range: $5.97-$6.49
  • 52-Week Range: $4.01-$16.95
  • Thursday's Volume: 777,000
  • Three-Month Average Volume: 854,297

 

TrueCar  (TRUE) , together with its subsidiaries, operates as an Internet-based information, technology, and communication services company. This stock traded up 5.6% to $6.40 in Thursday's trading session.

From a technical perspective, TrueCar ripped sharply higher on Thursday right above its previous breakout level at $5.89 a share with decent upside volume flows. This stock has been uptrending strong over the last few weeks, with shares moving higher off its low of $5.05 a share to its intraday high on Thursday of $6.50 a share. During that uptrend, shares of TrueCar have been making mostly higher lows and higher highs, which is bullish technical price action. This jump higher on Thursday is now quickly pushing shares of TrueCar within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out Thursday's intraday high of $6.50 a share to its 200-day moving average of $6.81 a share and then above more resistance at $6.89 a share with high volume.

Traders should now look for long-biased trades in TrueCar as long as it's trending above its previous breakout level at $5.89 a share or above its 50-day moving average of $5.57 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 854,297 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.50 to $8, or even $8.50 to $9 a share.

Sorrento Therapeutics

  • Thursday's Range: $6.64-$6.93
  • 52-Week Range: $4.25-$26.80
  • Thursday's Volume: 184,000
  • Three-Month Average Volume: 372,823

Sorrento Therapeutics  (SRNE) , a biopharmaceutical company, focuses on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing unmet medical needs worldwide. This stock traded up 1.9% to $6.90 in Thursday's trading session.

From a technical perspective, Sorrento Therapeutics spiked modestly higher on Thursday right above some near-term support at $6.34 a share with lighter-than-average volume. This stock has been uptrending very strong over the last month and change, with shares moving higher off its recent low of $4.62 a share to its recent high of $7.27 a share. During that uptrend, shares of Sorrento Therapeutics have been making mostly higher lows and higher highs, which is bullish technical price action. This bump to the upside on Thursday is now quickly pushing this stock within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $7 to $7.27 a share with high volume.

Traders should now look for long-biased trades in Sorrento Therapeutics as long as it's trending above some key near-term support at $6.34 a share or above more support at $6 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 372,823 shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8.50 to $9.40, or even its 200-day moving average of $9.98 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

More from Opinion

Tesla's $45,000 Model 3 Is a Half-Measure Meant to Protect Margins

Tesla's $45,000 Model 3 Is a Half-Measure Meant to Protect Margins

Flashback Friday: Happy Anniversary, Black Monday

Flashback Friday: Happy Anniversary, Black Monday

Vanguard Founder John Bogle Reflected on Black Monday: Rewind

Vanguard Founder John Bogle Reflected on Black Monday: Rewind

What You Need to Know About Black Monday 31 Years Later

What You Need to Know About Black Monday 31 Years Later

Taiwan Semi's Sales Outlook: Good News for Apple, Mixed Bag for Others

Taiwan Semi's Sales Outlook: Good News for Apple, Mixed Bag for Others